Floxuridine
- Atc Codes:L01BC
- CAS Codes:50-91-9
- PHARMGKB ID:50-91-9
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Greece: FUDR.
North America
Canada: FUDR; USA: FUDR.
Drug combinations
Chemistry
Floxuridine: C~9~H~11~FN~2~O~5~. Mw: 246.19. Uridine, 2′-deoxy-5-fluoro-. CAS-50-91-9 (1965).
Pharmacologic Category
Antineoplastic Agents; Antimetabolites; Pyrimidine Analog. (ATC-Code: L01BC).
Mechanism of action
Floxuridine is a fluorinated pyrimidine antagonist which inhibits DNA and RNA synthesis and methylation of deoxyuridylic acid to thymidylic acid.
Therapeutic use
Palliative management of GI adenocarcinoma metastasized to liver and considered incurable by surgery or other means of cancer therapy.
Pregnancy and lactiation implications
May cause fetal harm when administered to pregnant women. Teratogenic effects occurred in animals receiving floxuridine. Floxuridine should be used during pregnancy only in life-threatening situations or severe disease for which safer drugs cannot be used or are ineffective. Not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to floxuridine, fluorouracil, or any component of the formulation. Pregnancy.
Warnings and precautions
Hazardous agent. Risk for severe toxic reactions. Use with caution in depressed bone marrow function, hepatic or renal impairment. Use with caution in potentially serious infections. Use with caution in patients who have had previous use of alkylating agents, or high-dose pelvic radiation. Use with caution in poor nutritional status. May cause fetal harm. May produce severe hematologic toxicity, GI hemorrhage, or death. Anemia, leukopenia, and thrombocytopenia reported. Myocardial ischemia might occur. Acalculus cholecystitis and elevations in serum alkaline phosphatase, aminotransferase, bilirubin, and LDH concentrations reported. With hepatic arterial infusion, possible intra- and/or extrahepatic biliary sclerosis and liver cirrhosis.